This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
legalizes marijuana. It would open up a large market for the cannabis company, one that could help it drastically improve its revenue growth. Here are three reasons marijuana legalization in the U.S. In order to chase that market share, the company may end up using up a whole lot more cash. won't solve Tilray's problems.
Alongside Jus-Rol, Rinkelberg also acquired PA Ross Food Group, a UK sales and marketing company specialising in impulse, bakery, and frozen products. The CMA originally ordered Crlia to divest Jus-Rol after ruling in 2023 that the acquisition reduced competition in the UKs 100m ready-to-bake dough category.
The regulator, which launched the probe in December over competition concerns, confirmed on Wednesday that it will not escalate the merger to a further in-depth investigation. The company confirmed it is in early-stage discussion with private equity investors but emphasized that there is no certainty a public takeover offer will materialize.
The biggest merger in tech industry history just got the green light. On Tuesday, a federal judge in California denied the Federal Trade Commission's request for a preliminary injunction seeking to block Microsoft's monster $69 billion deal to acquire games-maker Activision Blizzard -- in effect, giving the merger the go-ahead.
Despite an unfavorable macroeconomic situation and cannabis' legal ambiguity in the U.S. Several positive developments, such as the steady progress of the SAFE Banking Act -- which could open up financial services to cannabis companies -- in the U.S. market, cannabis stocks demonstrated remarkable resilience in August.
The cannabis industry represents a huge growth opportunity for not just investors, but companies in other industries as well. But due to the federal ban on pot, many companies shy away from trying to collaborate or engage in mergers and acquisitions with marijuana producers. Boston Beer and Green Thumb to merge?
With a looming overhaul of US merger-and-acquisition law set to reshape the economics of the M&A-heavy pharmaceutical industry, 31 of its biggest players -- including Merck, Amgen, Abbvie, and Gilead -- formed an alliance to fight the reforms. You know, all the reasons giant companies acquire rivals in the first place.
Thanks to a combination of innovation, acquisitions, mergers, bankruptcies, legal judgments, competition, and even Acts of God, the stock market's "leaderboard" is constantly in flux. This is to say that Wall Street's largest companies today aren't liable to hold their positions five, 10, or even 20 years from now.
The cannabis industry continues to contend with mixed legislation and legalization at the state level while a total federal ban on marijuana remains in place. However, if you want some exposure to this space in your portfolio, here are two cannabis companies to consider. The REIT operates under a sale-leaseback structure.
Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of Horizon Therapeutics (NASDAQ: HZNP). The company's flagship product is Imcivree (setmelanotide). Image source: Getty Images.
In July 2019, the company let go of Bruce Linton, who at the time was an icon in the Canadian cannabis industry and co-CEO with Mark Zekulin. Current CEO David Klein ultimately ended up taking over, with the aim of improving the company's operations. The company recently wrapped up its 2024 fiscal year, which ended on March 31.
-based cannabis companies have excellent fundamentals that could lead to their success over the long run, very few Canadian growers stand a chance. When the Canadian market boomed after that nation's move to fully legalize cannabis, the companies did well. positioning itself to benefit if cannabis is ever federally legalized.
Canoo was not a normal IPO Canoo came public via a merger with a special purpose acquisitioncompany (SPAC) in late 2020. At the time, SPACs were a hot investment topic and companies were coming public at a rapid clip via this route. GOEV EPS Diluted (Quarterly) data by YCharts Companies can't lose money forever.
It's always interesting when a new company comes to market and doubly interesting when it's a spinoff. In reality, two new companies came out of the spinoff of Solventum (NYSE: SOLV) and 3M (NYSE: MMM) -- a newly created healthcare company and an industrial conglomerate without a healthcare business. Image source: Getty Images.
Nonetheless, these efforts have largely failed to halt the steady decline in cannabis company valuations in the country. SNDL: A company in transition Like nearly every Canadian cannabis outfit, SNDL is losing money right now. Put more succinctly, SNDL's liquor segment may not factor into the company's long term growth trajectory.
Without getting into the ugly details, the company's money laundering controls in the U.S. The fallout has been material for the bank , with the cancellation of a planned merger, added costs for improving its internal controls, and the need to set aside roughly $3 billion for the fines and legal costs the company expects to face.
The company continues to incur losses, and there are no significant changes coming to Canada's pot market next year, which could improve its prospects for profitability. It will pursue more acquisitions outside of the cannabis industry Tilray is in the cannabis business, but it has been diversifying outside of it.
Cvent”), an industry-leading meetings, events and hospitality technology provider, today announced the completion of its acquisition by an affiliate of private equity funds managed by Blackstone (“Blackstone”) for $8.50 Simpson Thacher & Bartlett LLP acted as legal counsel to Blackstone, and Evercore, Morgan Stanley & Co.
Rover” or the “Company”), the world’s largest online marketplace for pet care, today announced the completion of its acquisition by private equity funds affiliated with Blackstone (“Blackstone”) in an all-cash transaction valued at approximately $2.3 SEATTLE- February 27, 2024 – Rover Group, Inc. About Rover Group, Inc.
Canadian cannabis company Tilray Brands (NASDAQ: TLRY) has been on the right track ever since it merged with rival Aphria in 2021. It takes time for a big merger to reveal its full potential. It takes time for a big merger to reveal its full potential. With these acquisitions, management hopes to expand in the U.S.
History tells us that today's largest stocks are unlikely to be the biggest publicly traded companies 20 years from now. Ongoing innovation, mergers, acquisitions, legal judgments, competition, and a host of other factors are constantly shaking up the "leaderboard" on Wall Street. Image source: Getty Images.
If the company can find a way to bounce back, investing right now could deliver outsized results in the years ahead. The situation north of the border Tilray does extensive business in Canada, one of the few developed countries where recreational, adult uses of cannabis are legal. However, the company did not forget about the U.S.
in the mid-1960s, he's overseen a greater than 5,700,000% aggregate return in his company's Class A shares (BRK.A) and guided Berkshire to become only the ninth public company to reach the $1 trillion market cap plateau. Most people are familiar with the company because of its world-leading e-commerce segment. If the U.S.
Nasdaq: ROVR) (“Rover” or the “Company”), the world’s largest online marketplace for pet care, today announced that it has entered into a definitive agreement to be acquired by private equity funds managed by Blackstone (“Blackstone”) in an all-cash transaction valued at approximately $2.3 billion. “We
Before Canada legalized marijuana in 2018, Canopy Growth (NASDAQ: CGC) was seen as a top cannabis stock, an industry leader, and arguably one of the best stocks to invest in for people who were bullish on the prospects for marijuana reform at the time. based cannabis companies. It wouldn't result in legalization, however.
The strong cash flow will enable us to return to a debt-free status as we exit Q1 2025, paying off the remainder of the $1 billion debt inherited from the NuVasive merger. The acquisition of Nevro further expands our reach into the musculoskeletal market, adding an additional $2 billion market space for us to compete in and grow.
MiddleGround Capital, a Lexington, Kentucky-based operationally focused private equity firm that makes control investments in lower middle market industrial B2B and specialty distribution companies in North America and Europe, today announced the successful closing of MiddleGround Carbon CV, L.P.,
The company's dividend-growth streak currently qualifies it as a Dividend King , a term for companies that have increased their payouts for at least 50 years in a row. The company plans to reset its dividend now that it has completed the spin-off of its former healthcare business, Solventum. That's down from $9.24 billion.
The online sports betting company has been a favorite of "disruptive growth" investors like Cathie Wood, but it also once garnered the skepticism of short-sellers like Jim Chanos. The company actually posted rapidly improving financials, even if it hasn't hit profitability yet. in 2023, according to the company's November analyst day.
Johnson & Johnson (NYSE: JNJ) is a company that may look a lot different over the next several years. Top-selling drug Stelara is facing a patent cliff this year, the company has just spun off one of its business units, and there's no certainty that its legal issues will go away, either. billion price tag.
According to a press release, the fund was formed to recapitalise four portfolio companies from two previous funds – Renovus Capital Partners, and Renovus Capital Partners II – and will also provide those companies with an additional $60m for strategic add-on acquisitions. Source: Private Equity Wire Can’t stop reading?
A legal opinion on the other side of Planet Earth put some juice into Illumina 's (NASDAQ: ILMN) stock on Thursday. bump, on strong indication that a regulator's move against the company might soon be reversed. The gene-sequencing specialist saw its share price rise by over 3%, against the S&P 500 index's 0.3%
In June, the company completed the acquisition of Hexo, formerly one of the leaders in the Canadian cannabis space. 1 company in the country in terms of market share, with a 13% slice of the pie. It should also improve the company's margins, as Tilray's beverages unit is vastly superior to its other segments in this regard.
While the software titan inches closer to sealing its $69 billion deal to acquire game studio Activision Blizzard, its ongoing legal battle with the FTC resulted in a trove of internal documents pertaining to Microsoft's Xbox game device were leaked on Monday. We need a single big idea to rally the company around."
Axsome Therapeutics Biotech company Axsome Therapeutics (NASDAQ: AXSM) had a record year in 2022, with its stock increasing 104%. The company plans to use the proceeds in its pipeline development. million in international sales and brings in revenue for the company through licensing and royalties. Image source: Getty Images.
In other news, Paula Sambo of Bloomberg reports OMERS' private equity arm buys IT firm Integris from Frontenac: Omers Private Equity is buying a majority stake in Integris, a US cybersecurity and IT consulting company, from Chicago-based Frontenac Company LLC for an undisclosed amount. billion ($95.2 billion) as of June.
The sale forms part of Constellation's acquisition of Calpine. The merger will expand the footprint of the combined company across the continental US. is nearing an acquisition of Calpine Corp., in 2022, chief executive Joe Dominguez said he was interested in growing the company through mergers and acquisitions.
Yet she trumpets legal defeats as victories and keeps grinning like she’s winning.” Anesthesia Partners, a portfolio company in Texas. The editorial criticized the FTC’s novel legal theory that any asset manager could be sued for a company’s alleged anticompetitive conduct if it holds shares.
New Heritage Capital, a Boston-based private equity firm focused on mid-market, founder-owned businesses, has exited its investment in Revela Foods, a developer and manufacturer of dairy-flavoured ingredients and solutions, to ADM, a global human and pet nutrition company.
Schwartz advises companies and private equity and venture capital funds on their capital solution needs, from raising capital to deployment and management. Schwartz joins from Paul Hastings, where he was also a partner.
And for different reasons, investors in these three companies will hope that their new leaders will make a tangible difference in improving performance. William Brown took over as CEO of 3M (NYSE: MMM) on May 1 and has significantly influenced investors' thoughts about the company. CEOs make a difference. Image source: Getty Images.
This will help you better understand the entire mergers and acquisitions process, when to engage an advisor, and the role youll play as a business owner in your exit. Selling a business is a complex process that demands expertise in areas like financial analysis, marketing, and legal considerations.
Visit FOCUS Investment Banking’s Profile “The Peakstone Group is an investment bank that specializes in mergers and acquisitions advisory and capital raising for middle market clients. We create powerful marketing videos showcasing our client’s companies. We do ground-breaking, confidential global client marketing.
According to a press release, the fund was formed to recapitalise four portfolio companies from two previous funds – Renovus Capital Partners, and Renovus Capital Partners II – and will also provide those companies with an additional $60m for strategic add-on acquisitions.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content